BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2006;CD002092. [PMID: 16437440 DOI: 10.1002/14651858.cd002092.pub2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Moyes LH, Anderson JE, Forshaw MJ. Proposed follow up programme after curative resection for lower third oesophageal cancer. World J Surg Oncol 2010;8:75. [PMID: 20815912 DOI: 10.1186/1477-7819-8-75] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
2 Sgourakis G, Gockel I, Karaliotas C, Moehler M, Schimanski CC, Schmidberger H, Junginger T. Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. BMC Cancer 2012;12:70. [PMID: 22336151 DOI: 10.1186/1471-2407-12-70] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
3 Prasad NR, Karthigeyan M, Vikram K, Parthasarathy R, Reddy KS. Palliative radiotherapy in esophageal cancer. Indian J Surg 2015;77:34-8. [PMID: 25829709 DOI: 10.1007/s12262-013-0817-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
4 Chen Y, Wu X, Bu S, He C, Wang W, Liu J, Guo W, Tan B, Wang Y, Wang J. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci. 2012;103:1979-1984. [PMID: 22845557 DOI: 10.1111/j.1349-7006.2012.02393.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
5 Chen H, Zhou L, Yang Y, Yang L, Chen L. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma. Med Sci Monit 2018;24:4183-91. [PMID: 29915168 DOI: 10.12659/MSM.910326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Sharma N, Purkayastha A, Vishwanath S, Jaiswal P. To Compare and Determine the Diagnostic Accuracy of [18F]-fluorodeoxyglucose Positron Emission Tomography Scan in Predicting Pathological Response in Operated Carcinoma Esophagus Patients after Initial Neoadjuvant Chemoradiation and Neoadjuvant Chemotherapy. World J Nucl Med 2018;17:79-85. [PMID: 29719481 DOI: 10.4103/wjnm.WJNM_23_17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Agranovich A, McGahan CE, Gurjal A. Long-term survivorship of esophageal cancer patients treated with radical intent. Can J Gastroenterol 2008;22:393-8. [PMID: 18414715 DOI: 10.1155/2008/231878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
8 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
9 林琳, 曹鹏. 放化疗结合中医药治疗食管癌的临床研究进展. 世界华人消化杂志 2012; 20(35): 3505-3509 [DOI: 10.11569/wcjd.v20.i35.3505] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 de Vos-Geelen J, Geurts SM, van Putten M, Valkenburg-van Iersel LB, Grabsch HI, Haj Mohammad N, Hoebers FJ, Hoge CV, Jeene PM, de Jong EJ, van Laarhoven HW, Rozema T, Slingerland M, Tjan-Heijnen VC, Nieuwenhuijzen GA, Lemmens VE. Trends in treatment and overall survival among patients with proximal esophageal cancer. World J Gastroenterol 2019; 25(47): 6835-6846 [PMID: 31885424 DOI: 10.3748/wjg.v25.i47.6835] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 van Rossum PSN, Mohammad NH, Vleggaar FP, van Hillegersberg R. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15:235-249. [PMID: 29235549 DOI: 10.1038/nrgastro.2017.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
12 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Sun Y, Zhang XL, Mao QF, Liu YH, Kong L, Li MH. Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients. Curr Oncol 2018;25:e423-9. [PMID: 30464693 DOI: 10.3747/co.25.3895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Hawkins MA, Bedford JL, Warrington AP, Tait DM. Volumetric modulated arc therapy planning for distal oesophageal malignancies. Br J Radiol. 2012;85:44-52. [PMID: 21427179 DOI: 10.1259/bjr/25428720] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
15 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Cox S, Hurt C, Grenader T, Mukherjee S, Bridgewater J, Crosby T. The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 2017;125:154-9. [PMID: 28893415 DOI: 10.1016/j.radonc.2017.08.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
17 Sekii S, Ito Y, Harada K, Kitaguchi M, Takahashi K, Inaba K, Murakami N, Igaki H, Sasaki R, Itami J. Intrafraction esophageal motion in patients with clinical T1N0 esophageal cancer. Rep Pract Oncol Radiother 2018;23:398-401. [PMID: 30127681 DOI: 10.1016/j.rpor.2018.07.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
19 Wolf M, Zehentmayr F, Niyazi M, Ganswindt U, Haimerl W, Schmidt M, Hölzel D, Belka C. Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol. 2010;186:374-381. [PMID: 20582393 DOI: 10.1007/s00066-010-2137-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
20 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
21 Nishibuchi I, Murakami Y, Adachi Y, Imano N, Takeuchi Y, Tkahashi I, Kimura T, Urabe Y, Oka S, Tanaka S, Nagata Y. Effectiveness of salvage radiotherapy for superficial esophageal Cancer after non-curative endoscopic resection. Radiat Oncol 2020;15:133. [PMID: 32487186 DOI: 10.1186/s13014-020-01582-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer. 2011;11:466. [PMID: 22035459 DOI: 10.1186/1471-2407-11-466] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
23 Wolf MC, Zehentmayr F, Schmidt M, Hölzel D, Belka C. Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre. Radiat Oncol 2012;7:60. [PMID: 22501022 DOI: 10.1186/1748-717X-7-60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
24 Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J, Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J, Griffiths G, Nixon LS, Blazeby JM, Crosby T. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer 2015;113:603-10. [PMID: 26203761 DOI: 10.1038/bjc.2015.258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
25 Wolf MC, Stahl M, Krause BJ, Bonavina L, Bruns C, Belka C, Zehentmayr F. Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol. 2011;6:55. [PMID: 21615894 DOI: 10.1186/1748-717x-6-55] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
26 van Rossum PSN, Xu C, Fried DV, Goense L, Court LE, Lin SH. The emerging field of radiomics in esophageal cancer: current evidence and future potential. Transl Cancer Res 2016;5:410-23. [PMID: 30687593 DOI: 10.21037/tcr.2016.06.19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
27 van Nunen A, van der Sangen MJC, van Boxtel M, van Haaren PMA. Cone-Beam CT-based position verification for oesophageal cancer: Evaluation of registration methods and anatomical changes during radiotherapy. Tech Innov Patient Support Radiat Oncol 2017;3-4:30-6. [PMID: 32095564 DOI: 10.1016/j.tipsro.2017.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wahba HA, El-Hadaad HA, Abd-Ellatif EA. Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer. Med Oncol 2012;29:1693-8. [PMID: 21706368 DOI: 10.1007/s12032-011-0001-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
29 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25-43. [PMID: 30171414 DOI: 10.1007/s10388-018-0642-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 105] [Article Influence: 39.0] [Reference Citation Analysis]
30 Zhang R, Han D, Li L, Luo W, Liu J, Qian L. EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway. Cancer Manag Res 2020;12:9539-49. [PMID: 33061640 DOI: 10.2147/CMAR.S261182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ristau J, Thiel M, Katayama S, Schlampp I, Lang K, Häfner MF, Herfarth K, Debus J, Koerber SA. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity. Radiat Oncol 2021;16:23. [PMID: 33522923 DOI: 10.1186/s13014-021-01749-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Rawat S, Kumar G, Kakria A, Sharma MK, Chauhan D. Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required? J Gastrointest Cancer 2013;44:277-84. [PMID: 23389866 DOI: 10.1007/s12029-013-9477-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
33 Song GM, Tian X, Liu XL, Chen H, Zhou JG, Bian W, Chen WQ. Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis. Oncotarget 2017;8:37963-73. [PMID: 28415814 DOI: 10.18632/oncotarget.16302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Haefner MF, Lang K, Krug D, Koerber SA, Uhlmann L, Kieser M, Debus J, Sterzing F. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. J Radiat Res 2015;56:742-9. [PMID: 25907360 DOI: 10.1093/jrr/rrv022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
35 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24. [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 120] [Article Influence: 46.0] [Reference Citation Analysis]